SCI Abstract

search
+
Chapter One - Neuroanatomy of the nociceptive system: From nociceptors to brain networks
Update your browser to view ScienceDirect. ...
Chapter Two - Neuropathic pain – A clinical primer
Update your browser to view ScienceDirect. ...
Chapter Three - Quantitative Sensory Testing – From bench to bedside
Update your browser to view ScienceDirect. ...
Chapter Four - Regional and interregional functional and structural brain abnormalities in neuropathic pain
Update your browser to view ScienceDirect. ...
Chapter Five - Clinical neurophysiology of neuropathic pain
Update your browser to view ScienceDirect. ...
Chapter Six - Placebo effects in neuropathic pain conditions
Update your browser to view ScienceDirect. ...
Chapter Seven - Small fiber neuropathy
Update your browser to view ScienceDirect. ...
Chapter Eight - Modeling neuropathic pain in a dish
Update your browser to view ScienceDirect. ...
Chapter Nine - Molecular mechanisms of neuropathic pain
Update your browser to view ScienceDirect. ...
Chapter Ten - Exploring neuroinflammation: A key driver in neuropathic pain disorders
Update your browser to view ScienceDirect. ...
Chapter Eleven - Animal models of neuropathic pain
Update your browser to view ScienceDirect. ...
Chapter Twelve - Clinical pharmacology of neuropathic pain
Update your browser to view ScienceDirect. ...
Chapter Thirteen - Psychological, physical and complementary therapies for the management of neuropathic pain
Update your browser to view ScienceDirect. ...
Chapter Fourteen - Neuromodulation for neuropathic pain
Update your browser to view ScienceDirect. ...
Chapter Three - Insight gained from using animal models to study pain in Parkinson’s disease
Chapter Three - Insight gained from using animal models to study pain in Parkinson’s disease
Pain is one of the key non-motor symptoms experienced by a large proportion of people living with Parkinson’s disease (PD)...
Chapter Four - Investigating affective neuropsychiatric symptoms in rodent models of Parkinson’s disease
Chapter Four - Investigating affective neuropsychiatric symptoms in rodent models of Parkinson’s disease
Affective neuropsychiatric disorders such as depression, anxiety and apathy are among the most frequent non-motor symptoms...
Chapter Five - Macro and micro-sleep dysfunctions as translational biomarkers for Parkinson’s disease
Chapter Five - Macro and micro-sleep dysfunctions as translational biomarkers for Parkinson’s disease
Parkinson’s disease (PD) is the second most common neurodegenerative disease, afflicting about 1% of people over 65 years ...
Chapter Six - Review: Lower urinary tract dysfunction in animal models of Parkinson’s disease (PD): Translational aspects for the treatment of PD patients with overactive bladder
Chapter Six - Review: Lower urinary tract dysfunction in animal models of Parkinson’s disease (PD): Translational aspects for the treatment of PD patients with overactive bladder
Parkinson’s disease (PD) is a neurodegenerative disorder caused by the loss of dopaminergic neurons in the substantia nigr...
Chapter Seven - Executive dysfunction and cognitive decline, a non-motor symptom of Parkinson’s disease captured in animal models
Chapter Seven - Executive dysfunction and cognitive decline, a non-motor symptom of Parkinson’s disease captured in animal models
Parkinson’s disease (PD) is a complex and progressive neurodegenerative disorder primarily characterised by motor symptoms...
Chapter One - AUD in perspective
Chapter One - AUD in perspective
Alcohol is a major cause of pre-mature death and individual suffering worldwide, and the importance of diagnosing and trea...
Chapter Two - Alcohol and the dopamine system
Chapter Two - Alcohol and the dopamine system
The mesolimbic dopamine pathway plays a major role in drug reinforcement and is likely involved also in the development of...
Chapter Three - GABAergic mechanisms in alcohol dependence
Chapter Three - GABAergic mechanisms in alcohol dependence
In 2014, it was estimated that brain diseases were responsible for 35% of Europe’s disease burden, with addictions having ...
Chapter Four - Current treatments of alcohol use disorder
Chapter Four - Current treatments of alcohol use disorder
Emerging treatments for alcohol dependence reveal an intricate interplay of neurobiological, psychological, and circumstan...
Chapter Five - Repurposing drugs for treatment of alcohol use disorder
Chapter Five - Repurposing drugs for treatment of alcohol use disorder
Repurposing drugs for the treatment of alcohol dependence involves the use of drugs that were initially developed for othe...
Chapter Six - Substitution therapy for patients with alcohol dependence: Mechanisms of action and efficacy
Chapter Six - Substitution therapy for patients with alcohol dependence: Mechanisms of action and efficacy
Julien Guiraud is employed by Vergio, Clichy, France and was employed by D&A Pharma until March 2022.Wim van den Brink...
Chapter Seven - Reducing the harms of alcohol: nutritional interventions and functional alcohol alternatives
Chapter Seven - Reducing the harms of alcohol: nutritional interventions and functional alcohol alternatives
While GABA is the main inhibitory transmitter in the brain, the last three decades have seen an increased appreciation of ...
Chapter Eight - Designing and testing treatments for alcohol use disorder
Chapter Eight - Designing and testing treatments for alcohol use disorder
Developing new treatments for AUD or personalizing existing treatments for AUD requires extensive consideration of researc...
Chapter Nine - Phosphatidylethanol (B-PEth) and other direct and indirect biomarkers of alcohol consumption
Chapter Nine - Phosphatidylethanol (B-PEth) and other direct and indirect biomarkers of alcohol consumption
Correct information of the actual alcohol intake is essential to assess the correlation with alcohol risk level consumptio...
Setting the clinical context to non-motor symptoms reflected by Park-pain, Park-sleep, and Park-autonomic subtypes of Parkinson’s disease
Setting the clinical context to non-motor symptoms reflected by Park-pain, Park-sleep, and Park-autonomic subtypes of Parkinson’s disease
Dr James Parkinson, in 1817, first described a condition based on observation of motor features ranging from shaking to po...
Macro and micro-sleep dysfunctions as translational biomarkers for Parkinson’s disease
Macro and micro-sleep dysfunctions as translational biomarkers for Parkinson’s disease
Parkinson’s disease (PD) is the second most common neurodegenerative disease, afflicting about 1% of people over 65 years ...
Load More
format_indent_increase